Anne Schaap-Nutt

发表

Identification of Human Parainfluenza Virus Type 2 (HPIV-2) V Protein Amino Acid Residues That Reduce Binding of V to MDA5 and Attenuate HPIV-2 Replication in Nonhuman Primates

B. Murphy, P. Collins, A. Schmidt, 2011, Journal of Virology.

Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector

P. Kwong, B. Graham, Syed M. Moin, 2016, Journal of Virology.

Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate

P. Kwong, B. Graham, J. McLellan, 2015, Journal of Virology.

Vaccines Against Respiratory Syncytial Virus and Parainfluenza Viruses

R. Karron, B. Murphy, P. Collins, 2016 .

Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium.

P. Collins, Margaret A. Scull, R. Pickles, 2012, Virology.

ORF66 Protein Kinase Function Is Required for T-Cell Tropism of Varicella-Zoster Virus In Vivo

X. Che, M. Sommer, A. Arvin, 2006, Journal of Virology.

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children

R. Karron, P. Collins, U. Buchholz, 2013, Vaccine.

Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.

B. Murphy, P. Collins, Konrad C. Bradley, 2010, Virology.

Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys

B. Murphy, Margaret A. Scull, R. Pickles, 2010, Vaccine.

Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

M. St. Claire, B. Murphy, P. Collins, 2007, Vaccine.

Chimeric Bovine/Human Parainfluenza Virus Type 3 Expressing Respiratory Syncytial Virus (RSV) F Glycoprotein: Effect of Insert Position on Expression, Replication, Immunogenicity, Stability, and Protection against RSV Infection

P. Collins, U. Buchholz, S. Munir, 2014, Journal of Virology.

Identiﬁcation of Human Parainﬂuenza Virus Type 2 (HPIV-2) V Protein Amino Acid Residues That Reduce Binding of V to MDA5 and Attenuate HPIV-2 Replication in Nonhuman Primates (cid:1)

P. Collins, A. Schmidt, Emérito Amaro-Carambot, 2011 .

The Aberrant Gene-End Transcription Signal of the Matrix M Gene of Human Parainfluenza Virus Type 3 Downregulates Fusion F Protein Expression and the F-Specific Antibody Response In Vivo

P. Collins, S. Munir, Emérito Amaro-Carambot, 2015, Journal of Virology.

Herpes simplex virus‐1 induces expression of a novel MxA isoform that enhances viral replication

M. Reichelt, X. Che, M. Sommer, 2011, Immunology and cell biology.

Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates

B. Murphy, P. Collins, Margaret A. Scull, 2009, Virology.

Progress in the development of human parainfluenza virus vaccines

R. Karron, P. Collins, A. Schmidt, 2011, Expert review of respiratory medicine.

Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.

P. Collins, A. Schmidt, Henrick Schomacker, 2012, Current opinion in virology.

Anti-metastatics: an overview of drug candidates in current pipelines.

F. Entschladen, D. Thyssen, Anne Schaap-Nutt, 2014, Current pharmaceutical design.

Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children.

R. Karron, B. Murphy, Bhagvanji Thumar, 2015, Journal of the Pediatric Infectious Diseases Society.